A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
A phase 1/2 trial of E-EDV-D682, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Engeneic Pty Limited, now recruiting.
Overview
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07049055 by Engeneic Pty Limited, with 144 participants planned, started 2026-01-12 and due to reach its primary completion in 2028-09. Interventions recorded: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.. Conditions listed: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialStudy to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C
Shares Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer